Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

Leukemia

Volumn 14, Issue 12, 2000, Pages 2205-2222

  Schrappe, M ^a   Reiter, A ^b   Zimmermann, M ^a   Harbott, J ^b   Ludwig, W D ^c   Henze, G ^c   Gadner, H ^d   Odenwald, E ^a   Riehm, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Childhood ALL; CNS relapse; Cranial radiotherapy; Early treatment response; Leukemia; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOPLASM PROTEIN; DAUNORUBICIN; DEXAMETHASONE; DNA; ETOPOSIDE; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN M; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; PHYCOERYTHRIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENIPOSIDE; TIOGUANINE; TUMOR ANTIGEN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GERMANY; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; INFANT; INFORMATION PROCESSING; LEUKOCYTOSIS; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SKULL IRRADIATION; SWITZERLAND; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034517924     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401973     Document Type: Article

References (75)

1. Prevention of central nervous system leukemia by irradiation
2. Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes - Erfahrungsbericht nach 6 Jahren (The West Berlin therapy study of acute lymphoblastic leukemia in childhood - Report after 6 years)
3. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976
4. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia
5. Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen (Results of study BFM 76/79 for treatment of acute lymphoblastic leukemia in childhood and adolescence)
6. Acute lymphoblastic leukemia: Treatment results in three BFM studies (1970-1981)
7. Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: Prognostische Bedeutung und praktische Anwendung (Assessment of tumor cell load in acute lymphoblastic leukemia: And practical use)
8. Die Behandlung der akuten lymphoblastischen Leukämie im Kindes und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81 (Treatment of acute lymphoblastic leukemia in childhood and adolescence: Multicenter trial ALL-BFM 81)
9. Results and significance of six randomized trials in four consecutive ALL-BFM trials
10. Die Corticosteroidabhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) (The in vivo response on an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83))
11. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
12. Intensive ALL-type therapy without local radiotherapy phoblastic a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report
13. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM 90
14. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome
15. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia
16. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials CoALL-05-92
17. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment
18. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
19. Proposals for the classification of the acute leukaemias
20. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the 'BFM Family' cooperative group
21. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
22. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM 87
23. Proposals for the immunological classification of acute leukaemias
24. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: Experience of the BFM trials
25. Frequency and clinical significance of DNA aneuploidy in acute leukemia
26. Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem Rezidivrisiko
27. Acute lymphoblastic leukemia: Current status of therapy in children
28. Nonparametric estimation from incomplete observations
29. Evaluation of survival data and two new rank order statistics arising in its consideration
30. A class of K-sample tests for comparing the cumulative incidence of a competing risk
31. Risk adapted treatment in childhood acute lymphoblastic leukemia: Data from the Berlin-Frankfurt-Münster group
32. Treatment of acute lymphoblastic leukemia - 30 years' experience at St Jude children's research hospital
33. Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials
34. Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials
35. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK medical research council trial UKALL X, Medical research council working party on childhood leukaemia
36. Treatment of childhood acute lymphoblastic leukemia: Results of dana-farber cancer institute/children's hospital acute lymphoblastic leukemia consortium protocol 85-01
37. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A childrens cancer group phase III trial
38. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the childrens cancer group study CCG-106
39. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia
40. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy
41. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
42. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Munster and Dana-Farber cancer Institute protocols
43. Role of cranial radiotherapy for childhood T cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
44. Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of childhood acute lymphoblastic leukemia: Significantly lower risk without cranial radiotherapy
45. Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia
46. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
47. Prophylaxis and treatment of meningeosis in childhood acute lymphoblastic leukemia
48. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood ALL
49. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features
50. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the childrens cancer group
51. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia
52. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
53. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs
54. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: A pediatric oncology group study
55. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage vs T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity
56. Pharmacogenomics: Translating functional genomics into rational therapeutics
57. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
58. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
59. Ph+ childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
60. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
61. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia
62. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review
63. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor chain sequences
64. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients
65. The immunologic detection of residual disease in acute leukemia
66. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
67. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM study group
68. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
69. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
70. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
71. Improved outcome for acute lymphoblastic leukemia in children of a developing country: Results of the Chilean national trial PINDA 87
72. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: Results of DCLSG protocol ALL-7 (1988-1991)
73. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study
74. Favorable outcome of B cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group